Recommendations for skin cancer consultation and surgery during COVID-19 pandemic

As a result of the outbreak of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and government lockdown measures, healthcare systems were challenged worldwide. Medical doctors were faced with prioritization of non-COVID19 medical problems in order to reduce potential exposures and to mobilize staff and resources for COVID-19 care. On the other hand, decreases in some non-COVID19 health problems have been observed, e.g. myocardial infarction, newly diagnosed cancers among which esp. skin cancer, ... and there is concern that delay in these may negatively affect patient outcome.1-3 In this respect, it is important to define and communicate recommendations on prioritization of non-COVID19 related health care.

In this position paper, we describe recommendations developed by the Belgian Association of Dermato-Oncology (BADO) for prioritization of patients in the field of dermato-oncology during COVID19 pandemic without compromising quality of care and safety. BADO was founded in 2012, and the board consists of a mix of dermatologists, oncologists and surgeons. Its main goals are to promote multidisciplinary approach of dermato-oncology, to exchange scientific knowledge about dermato-oncology and to work on treatment recommendations for different skin cancer types.

These (COVID-19) recommendations are based on estimated potentially harmful effects by delaying a specific consultation type as also discussed in the letter of Tejera-Vaquezio.1 We categorized dermato-oncology care into urgent (no delay), semi-urgent (delay for max 8–12 weeks) and low priority (more than 12 weeks delay acceptable) (Tables 1–3). In addition, measures for limiting viral transmission during consultation and surgery are described (Tables 4–6).

In conclusion, the COVID-19 outbreak posed significant challenges to medical staff to offer optimal and timely care in non-COVID19 health problems at the same time keeping the risk of COVID19 spread as low as possible. In the last months, proposals for triage in several health conditions have been published especially in oncology including skin cancer.4-9 BADO developed recommendations to prioritize dermato-oncological care on a national level in Belgium. In the circumstances of the COVID19 pandemic, the approval and refunding of tele/video-consultations by the government was accelerated but for skin cancer treatment and follow-up teleconsultations are often sub-optimal.10,11

These recommendations were needed to take on a nationwide similar approach for the different indications in dermato-oncology; it was also a way to monitor replanning of postponed consultations since acceptable delay period was defined for different indications in dermato-oncology. Because of the fast changing situation, the introduction of the guidelines mentions that ‘these recommendations could serve as a guidance and are based on a general weighing of pros/cons. They need to be tuned according to the evolving situation and advices for COVID19 by the government and the weighing of the pros/cons for the individual patient’.

For the moment, the lockdown measures in Belgium have been gradually decreased and care has returned to (nearly) normal levels taking into account basic preventive measures

Table 1 Urgent care: no postponement

| Referral for possible melanoma or other skin cancer |
| Confirmed new melanoma and its surgery |
| Confirmed new SCC |
| Confirmed new other skin cancer, e.g. Merkel cell CA, angiosarcoma |
| Skin cancer with systemic treatment† |
| Excision suspicious nevus |
| Follow-up stage II and III melanoma within first 2 years of follow-up |
| Follow-up SCC: moderate/poor differentiation or prior metastasis or transplant patient or history of multiple SCCs |
| Follow-up multiple primary melanomas |
| Planned digital dermoscopy follow-up of specific lesion(s) after 3–4 months |
| Any patient with skin cancer history who is worried (first triage by teleconsultation) |

†Systemic treatment options with reduced frequency of hospital visits need to be considered.

Table 2 Semi-urgent care: these indications can be postponed, but need to be replanned within 8–12 weeks

| Follow-up stage II and III melanoma after 2 years of follow-up |
| Follow-up stage I melanoma and in situ melanoma |
| Follow-up low-risk SCC |
| Confirmed new BCC (for BCC in the face surgery should already be planned) |
| Confirmed Morbus Bowen |
| Follow-up multiple BCC |
| Dysplastic nevus syndrome with family history of melanoma |
Table 3 Low priority indications can be postponed beyond 12 weeks

- Follow-up BCC
- Follow-up dysplastic nevus syndrome with negative personal/family history of melanoma (annual check)
- Follow-up actinic keratosis

Table 4 Practical planning of the consultation

- Consider teleconsultation whenever possible.
- This is especially important in patients at risk for serious COVID19 infection (e.g. old age – immunosuppressive R/other comorbidities)
- Prior to consultation, ask the patient:
  a if he/she has has (had) any fever- or cough- or flu-like symptoms
  b to bring a face mask if he/she has one

Table 5 General precautions during the consultation

- Patients should be spaced at least 1.5 m apart while waiting.
- Patient should clean their hands with soap and water for at least 20 s. Alternatively they can be asked to use alcohol 70% desinfectant
- If patients have a face mask (or the dermatology practice can provide one) they should be asked to wear it.
- Patients with fever- or cough- or flu-like symptoms in the past 4 weeks or patients who tested COVID19 positive should wear a face mask up to 30 days after the start of their first symptoms/positive COVID-19 PCR testing.
- The dermatologist who performs a total body examination with dermoscopy should wear a face mask and wash/desinfect hands.
- The dermatologist can consider to wear gloves during examination.
- The dermatoscope should be disinfected with an 70% alcohol solution. The use of a protective cap or polyvinyl chloride (PVC) food wrap on the dermatoscope should be considered. An alcohol solution or gel can be used as interface medium for dermoscopy12
- Dermoscopy at certain sites like the area under the face mask should be avoided as much as possible12

Table 6 Precautions during surgery

1. Outpatient intervention outside face mask area
   Patient wears face mask
   Doctor wears face mask and gloves and normal surgical clothing

2. Outpatient intervention in mask area of the face
   COVID testing (SWAB screening day before) negative
   If testing is not available, treat the patients as potentially positive and increase doctor's protection: (FFP2) mask and extra protection (e.g. shield and extra surgical apron over surgical clothing)

3. Inpatient surgery
   Consider COVID testing in all patients prior to hospitalization

L. Brochez,1,2 J.F. Baurain,2 V. Del Marmol,3 A. Nikkels,4 V. Kruse,5 F. Sales,6 M. Stas,7 A. Van Laethem,8 M. Garmyn8

1Dermatology, University Hospital Gent, Ghent, Belgium, 2Centre du Cancer, Cu Saint-Luc/UCL, Brussels, Belgium, 3Dermatology, Hospital Erasme, Université Libre de Bruxelles, Brussels, Belgium, 4Dermatology, CHU du Sart Tilman, University of Liège, Liège, Belgium, 5Oncology, University Hospital Gent, Ghent, Belgium, 6Surgery, Bordet Institute, Brussels, Belgium, 7Oncological Surgery, University Hospital Leuven, Leuven, Belgium, 8Dermatology, University Hospital Leuven, Leuven, Belgium

*Correspondence: L. Brochez. E-mail: lieve.brochez@ugent.be

Linked articles: COVID-19 SPECIAL FORUM. J Eur Acad Dermatol Venereol 2020; 34: e433–e466.

References
1 Solomon MD, McNulty EJ, Rana JS et al. The Covid-19 pandemic and the incidence of acute myocardial infarction. N Engl J Med 2020. https://doi.org/10.1056/NEJMoa2015630
2 Dinmohamed AG, Visser O, Verhoeven RHA et al. Fewer cancer diagnoses during the COVID-19 epidemic in the Netherlands. Lancet Oncol 2020; 21: 750–751.
3 Tejera-Vaquerizo A, Nagore E. Estimated effect of COVID-19 lockdown on melanoma thickness and prognosis: a rate of growth model. J Eur Acad Dermatol Venereol 2020. https://doi.org/10.1111/jdv.16555
4 Tagliaferri L, Di Stefani A, Shinzari G et al. Skin cancer triage and management during COVID-19 pandemic. J Eur Acad Dermatol Venereol. 2020; 34: 1136–1139.
5 Borchert A, Baumgarten L, Dalela D et al. Managing urology consultations during COVID-19 pandemic: application of a structured care pathway. Urology 2020; 4295: 7–11.
6 Pothuri B, Alvarez Secord A, Armstrong DK et al. Anti-cancer therapy and clinical trial considerations for gynecologic oncology patients during the COVID-19 pandemic crisis. Gynecol Oncol 2020; 158: 16–24.
7 de Azambuja E, Trapani D, Loibl S et al. ESMO management and treatment adapted recommendations in the COVID-19 era: breast cancer. ESMO Open 2020; 5(Suppl 3): e000793.
8 Di Ciaccio P, McCaughan G, Trotman I et al. Australian and New Zealand consensus statement on the management of lymphoma, chronic
lymphocytic leukaemia and myeloma during the COVID-19 pandemic. Intern Med J 2020; 50: 667–679. https://doi.org/10.1111/imj.14859

9 López V, Vázquez T, Alonso-Titos J et al. Recommendations on management of the SARS-CoV-2 coronavirus pandemic (Covid-19) in kidney transplant patients. Nefrologia 2020; 40: 265–271.

10 Valentino LA, Skinner MW Pipe S. The role of telemedicine in the delivery of healthcare in the COVID-19 Pandemic. Haemophilia 2020. https://doi.org/10.1111/hae.14044

11 Sharma A, Jindal V, Singla P, Goldust M, Mhatre M. Will Teledermatology be the silver lining during and after COVID-19? Dermatol Ther 2020; 22: e13643.

12 Jakhar D, Kaur I, Kaul S. Art of performing dermoscopy during the times of coronavirus disease (COVID-19): simple change in approach can save the day! J Eur Acad Dermatol Venereol 2020; 34: e242–e244. https://doi.org/10.1111/jdv.16412

DOI: 10.1111/jdv.16772